Home > Press > Nanoparticle-Delivered RNA Interference Drug Stops Head and Neck Cancer Growth
![]() |
Abstract:
A nanoparticle drug delivery vehicle for small interfering RNA molecules (siRNA), that is already being tested in human clinical trials, now shows promise for the treatment of head and neck cancer. Dong Shin, of Emory University, and Mark E. Davis, of the Nanosystems Biology Cancer Center at the California Institute of Technology, led this study. The results were published in the Journal of Controlled Release.
Drugs based on siRNA technology are designed to turn off the production of specific proteins that are critically involved in a disease such as cancer. While a significant body of evidence has shown this approach to targeting critical disease pathways can be highly effective, siRNA molecules themselves do not survive in the blood stream. Dr. Davis and his colleagues have long been leaders in the effort to use tumor-targeted nanoparticles to protect siRNAs from degradation and deliver them to where they are needed in the body.
In this study Dr. Davis's group, which had previously developed a nanoparticle that encapsulates a siRNA agent aimed at a protein known as RRM2, has teamed up with Dr. Shin's group to evaluate the effectiveness of these particles in head and neck cancer. RRM2, when over expressed in these tumor types, plays an active role in tumor progression and in the development of drug resistance. Initial tests on head and neck tumor cells growing in culture showed that this construct was taken up by the tumor cells, and as a result growth of the cells was inhibited substantially. The investigators obtained similar results when they tested the drug on cultured non-small cell lung cancer cells.
Based on these findings, the researchers tested the siRNA-loaded nanoparticle in a mouse model of human head and neck cancer. One intravenous injection of the drug shut down production of RRM2 for at least 10 days, with the nanoparticle being present in the tumor for three days. Four injections given over 10 days triggered a substantial amount of tumor cell death and significantly reduced tumor progression. The researchers note that they did not observe any adverse effects or changes in body weight during the course of therapy. They also showed that the drug had no effect on RRM2 production in the liver.
####
About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © The National Cancer Institute (NCI)
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related Links |
Related News Press |
News and information
Flexible electronics integrated with paper-thin structure for use in space January 17th, 2025
Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025
Govt.-Legislation/Regulation/Funding/Policy
Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025
Chainmail-like material could be the future of armor: First 2D mechanically interlocked polymer exhibits exceptional flexibility and strength January 17th, 2025
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Discoveries
Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025
Announcements
Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025
The National Space Society Congratulates SpaceX on Starship’s 7th Test Flight: Latest Test of the Megarocket Hoped to Demonstrate a Number of New Technologies and Systems January 17th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |